Cancer Immunology, Immunotherapy

, Volume 54, Issue 6, pp 517–525

New developments in dendritic cell–based vaccinations: RNA translated into clinics

  • Frank Grünebach
  • Martin R. Müller
  • Peter Brossart


Dendritic cells (DCs) are the most powerful antigen-presenting cells that induce and maintain primary immune responses in vitro and in vivo. The development of protocols for the ex vivo generation of DCs provided a rationale for designing and developing DC-based vaccination studies for the treatment of infectious and malignant diseases. Recently, it was shown that DCs transfected with ribonucleic acid (RNA) coding for a tumour-associated antigen or whole tumour RNA are able to induce potent antigen and tumour-specific T-cell responses directed against multiple epitopes. The first RNA-transfected-DC-based clinical studies have shown that this form of vaccination is feasible and safe. In some cases, clinical responses were observed, but the preliminary data require further extensive investigations that should address the technical and biological problems of manipulating human DCs, as well as the development of standardised protocols and definitions of clinical settings.


CTL Dendritic cells Immunotherapy RNA transfection 


  1. 1.
    Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86–89CrossRefPubMedGoogle Scholar
  2. 2.
    Andreason GL, Evans GA (1988) Introduction and expression of DNA molecules in eukaryotic cells by electroporation. Biotechniques 6:650–660Google Scholar
  3. 3.
    Asai T, Storkus WJ, Whiteside TL (2000) Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol 7:145–154CrossRefPubMedGoogle Scholar
  4. 4.
    Bakker AB, Marland G, de Boer AJ, Huijbens RJ, Danen EH, Adema GJ, Figdor CG (1995) Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 55:5330–5334PubMedGoogle Scholar
  5. 5.
    Baum C, Richters A, Ostertag W (1999) Retroviral vector-mediated gene expression in hematopoietic cells. Curr Opin Mol Ther 1:605–612PubMedGoogle Scholar
  6. 6.
    Bernhard H, Disis ML, Heimfeld S, Hand S, Gralow JR, Cheever MA (1995) Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 55:1099–1104PubMedGoogle Scholar
  7. 7.
    Bevan MJ (1976) Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143:1283–1288CrossRefPubMedGoogle Scholar
  8. 8.
    Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465–472CrossRefPubMedGoogle Scholar
  9. 9.
    Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E (2000) Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 60:1028–1034PubMedGoogle Scholar
  10. 10.
    Brossart P, Bevan MJ (1997) Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 90:1594–1599PubMedGoogle Scholar
  11. 11.
    Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ (1997) Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 158:3270–3276Google Scholar
  12. 12.
    Brossart P, Grünebach F, Stuhler G, Reichardt VL, Möhle R, Kanz L, Brugger W (1998) Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood 92:4238–4247PubMedGoogle Scholar
  13. 13.
    Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W (1998) Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58:732–736PubMedGoogle Scholar
  14. 14.
    Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309–4317PubMedGoogle Scholar
  15. 15.
    Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A (1997) Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782–787CrossRefPubMedGoogle Scholar
  16. 16.
    Cella M, Sallusto F, Lanzavecchia A (1997) Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9:10–16Google Scholar
  17. 17.
    Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr (1996) Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183:283–387CrossRefPubMedGoogle Scholar
  18. 18.
    Cerundolo V, Hermans IF, Salio M (2004) Dendritic cells: a journey from laboratory to clinic. Nat Immunol 5:7–10Google Scholar
  19. 19.
    Chang JW, Peng M, Vaquerano JE, Zhou YM, Clinton RA, Hyun WC, Giedlin MA, Leong SP (2000) Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies. Anticancer Res 20:1329–1336PubMedGoogle Scholar
  20. 20.
    Colosimo A, Goncz KK, Holmes AR, Kunzelmann K, Novelli G, Malone RW, Bennett MJ, Gruenert DC (2000) Transfer and expression of foreign genes in mammalian cells. Biotechniques 29:314–324Google Scholar
  21. 21.
    Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr (1996) DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2:1122–1128CrossRefPubMedGoogle Scholar
  22. 22.
    Dauer M, Obermaier B, Herten J, Haerle C, Pohl K, Rothenfusser S, Schnurr M, Endres S, Eigler A (2003) Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 170:4069–4076Google Scholar
  23. 23.
    Drummond DR, Armstrong J, Colman A (1985) The effect of capping and polyadenylation on the stability, movement and translation of synthetic messenger RNAs in Xenopus oocytes. Nucleic Acids Res 13:7375–7394PubMedGoogle Scholar
  24. 24.
    Drummond DR, McCrae MA, Colman A (1985) Stability and movement of mRNAs and their encoded proteins in Xenopus oocytes. J Cell Biol 100:1148–1156CrossRefPubMedGoogle Scholar
  25. 25.
    Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10:475–480CrossRefPubMedGoogle Scholar
  26. 26.
    Fisch P, Kohler G, Garbe A, Herbst B, Wider D, Kohler H, Schaefer HE, Mertelsmann R, Brugger W, Kanz L (1996) Generation of antigen-presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients. Eur J Immunol 26:595–600Google Scholar
  27. 27.
    Flechsler I, Surovoy A, Charisse K, Bayer E, Jung G (1998) Comparison of antisense vectors and antisense oligonucleotides delivered by means of the new cationic lipids unifectin and maxifectin. Adv Exp Med Biol 451:469–472PubMedGoogle Scholar
  28. 28.
    Galili G, Kawata EE, Smith LD, Larkins BA (1988) Role of the 3′-poly(A) sequence in translational regulation of mRNAs in Xenopus laevis oocytes. J Biol Chem 263:5764–5770Google Scholar
  29. 29.
    Gilboa E (2001) The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2:789–792Google Scholar
  30. 30.
    Glaspy JA (2002) Therapeutic options in the management of renal cell carcinoma. Semin Oncol 29:41–46CrossRefGoogle Scholar
  31. 31.
    Grünebach F, Müller MR, Nencioni A, Brossart P (2003) Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 10:367–374CrossRefPubMedGoogle Scholar
  32. 32.
    Guarnieri FG, Arterburn LM, Penno MB, Cha Y, August JT (1993) The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1. J Biol Chem 268:1941–1946Google Scholar
  33. 33.
    Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621–667CrossRefPubMedGoogle Scholar
  34. 34.
    Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S (2003) ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425:397–402CrossRefPubMedGoogle Scholar
  35. 35.
    Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J (2000) Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 164:5508–5514Google Scholar
  36. 36.
    Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E, Vieweg J (2001) Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 166:2953–2960Google Scholar
  37. 37.
    Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109:409–417CrossRefPubMedGoogle Scholar
  38. 38.
    Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ (2000) Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 96:1857–1864PubMedGoogle Scholar
  39. 39.
    Hoerr I, Obst R, Rammensee HG, Jung G (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30:1–7Google Scholar
  40. 40.
    Höltl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH Jr, Thurnher M (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8:3369–3376PubMedGoogle Scholar
  41. 41.
    Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, Laplante A, Princiotta MF, Thibault P, Sacks D, Desjardins M (2003) Phagosomes are competent organelles for antigen cross-presentation. Nature 425:402–406CrossRefPubMedGoogle Scholar
  42. 42.
    Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52–58CrossRefPubMedGoogle Scholar
  43. 43.
    Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, Pack M, Subklewe M, Sauter B, Sheff D, Albert M, Bhardwaj N, Mellman I, Steinman RM (1998) Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 188:2163–2173CrossRefPubMedGoogle Scholar
  44. 44.
    Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, Reis e Sousa C, Germain RN, Mellman I, Steinman RM (2000) The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med 191:927–936CrossRefPubMedGoogle Scholar
  45. 45.
    Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL (1999) Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 163:699–707Google Scholar
  46. 46.
    Kobayashi T, Yamanaka R, Homma J, Tsuchiya N, Yajima N, Yoshida S, Tanaka R (2003) Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 52:632–637CrossRefPubMedGoogle Scholar
  47. 47.
    Krieg PA, Melton DA (1984) Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res 12:7057–7070PubMedGoogle Scholar
  48. 48.
    Lapointe R, Royal RE, Reeves ME, Altomare I, Robbins PF, Hwu P (2001) Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J Immunol 167:4758–4764PubMedGoogle Scholar
  49. 49.
    Littauer UZ, Soreq H (1982) The regulatory function of poly(A) and adjacent 3′ sequences in translated RNA. Prog Nucleic Acid Res Mol Biol 27:53–83PubMedGoogle Scholar
  50. 50.
    Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297–302CrossRefPubMedGoogle Scholar
  51. 51.
    Milazzo C, Reichardt VL, Müller MR, Grünebach F, Brossart P (2003) Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101:977–982CrossRefPubMedGoogle Scholar
  52. 52.
    Morse MA, Zhou LJ, Tedder TF, Lyerly HK, Smith C (1997) Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy. Ann Surg 226:6–16CrossRefPubMedGoogle Scholar
  53. 53.
    Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, Boczkowski D, Proia A, Neidzwiecki D, Clavien PA, Hurwitz HI, Schlom J, Gilboa E, Lyerly HK (2003) Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 21:341–349CrossRefPubMedGoogle Scholar
  54. 54.
    Müller MR, Grünebach F, Nencioni A, Brossart P (2003) Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol 170:5892–5896Google Scholar
  55. 55.
    Müller MR, Tsakou G, Grünebach F, Schmidt SM, Brossart P (2004) Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood 103:1763–1769CrossRefPubMedGoogle Scholar
  56. 56.
    Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E (1998) Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 16:364–369Google Scholar
  57. 57.
    Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E (2000) Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6:1011–1017CrossRefPubMedGoogle Scholar
  58. 58.
    Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, Lyerly HK (2002) Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 235:540–549CrossRefPubMedGoogle Scholar
  59. 59.
    Nencioni A, Müller MR, Grünebach F, Garuti A, Mingari MC, Patrone F, Ballestrero A, Brossart P (2003) Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. Cancer Gene Ther 10:209–214CrossRefPubMedGoogle Scholar
  60. 60.
    Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332PubMedGoogle Scholar
  61. 61.
    Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, Bornkamm GW, Mautner J (2003) Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 33:1250–1259Google Scholar
  62. 62.
    Paczesny S, Banchereau J, Wittkowski KM, Saracino G, Fay J, Palucka AK (2004) Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med 199:1503–1511CrossRefPubMedGoogle Scholar
  63. 63.
    Ponsaerts P, Van Tendeloo VF, Berneman ZN (2003) Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol 134:378–384PubMedGoogle Scholar
  64. 64.
    Porgador A, Gilboa E (1995) Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182:255–260CrossRefPubMedGoogle Scholar
  65. 65.
    Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P (1996) Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 56:5672–5677PubMedGoogle Scholar
  66. 66.
    Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83–93CrossRefPubMedGoogle Scholar
  67. 67.
    Roy CR (2003) Immunology: professional secrets. Nature 425:351–352CrossRefPubMedGoogle Scholar
  68. 68.
    Sallusto F, Cella M, Danieli C, Lanzavecchia A (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182:389–400CrossRefPubMedGoogle Scholar
  69. 69.
    Scott-Taylor TH, Pettengell R, Clarke I, Stuhler G, La Barthe MC, Walden P, Dalgleish AG (2000) Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 1500:265–279CrossRefPubMedGoogle Scholar
  70. 70.
    Shaif-Muthana M, McIntyre C, Sisley K, Rennie I, Murray A (2000) Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res 60:6441–6447PubMedGoogle Scholar
  71. 71.
    Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P (1997) Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 186:1213–1221CrossRefPubMedGoogle Scholar
  72. 72.
    Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A (2000) Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther 7:2028–2035CrossRefPubMedGoogle Scholar
  73. 73.
    Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey D, Turaga V, Higgins J, Boczkowski D, Gilboa E, Dannull J (2002) Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 62:5041–5048PubMedGoogle Scholar
  74. 74.
    Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J (2003) Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63:2127–2133PubMedGoogle Scholar
  75. 75.
    Surovoy A, Flechsler I, Jung G (1998) A novel series of serum-resistant lipoaminoacid compounds for cellular delivery of plasmid DNA. Adv Exp Med Biol 451:461–467PubMedGoogle Scholar
  76. 76.
    Thornburg C, Boczkowski D, Gilboa E, Nair SK (2000) Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy. J Immunother 23:412–418Google Scholar
  77. 77.
    Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den DP, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669–1678CrossRefPubMedGoogle Scholar
  78. 78.
    Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, Pilarski LM, Anderson KC (1999) Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 93:1287–1298PubMedGoogle Scholar
  79. 79.
    Turley SJ, Inaba K, Garrett WS, Ebersold M, Unternaehrer J, Steinman RM, Mellman I (2000) Transport of peptide-MHC class II complexes in developing dendritic cells. Science 288:522–527CrossRefPubMedGoogle Scholar
  80. 80.
    Ueno H, Tcherepanova I, Reygrobellet O, Laughner E, Ventura C, Palucka AK, Banchereau J (2004) Dendritic cell subsets generated from CD34(+) hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses. J Immunol Methods 285:171–180CrossRefPubMedGoogle Scholar
  81. 81.
    Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98:49–56CrossRefPubMedGoogle Scholar
  82. 82.
    Weissman D, Ni H, Scales D, Dude A, Capodici J, McGibney K, Abdool A, Isaacs SN, Cannon G, Kariko K (2000) HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol 165:4710–4717Google Scholar
  83. 83.
    Whiteside TL, Odoux C (2004) Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 53:240–248CrossRefPubMedGoogle Scholar
  84. 84.
    Zakian VA (1995) Telomeres: beginning to understand the end. Science 270:1601–1607PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Frank Grünebach
    • 1
  • Martin R. Müller
    • 1
  • Peter Brossart
    • 1
  1. 1.Department of Internal Medicine II, Division of Hematology, Immunology, and OncologyUniversity of TübingenTübingenGermany

Personalised recommendations